EMBC vs ZTS: fair value comparison
Embecta Corp. and Zoetis Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our discount ranking. ZTS carries the stronger quality grade.
| EMBC | ZTS | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $3.72 | $75.81 |
| 12-month range | $3.29–$14.27 | $77.10–$144.35 |
| Sector rank | #3 of 113 Healthcare | #5 of 113 Healthcare |
| Quality grade | C- | C |
| Momentum grade | B | — |
| Leverage | Low | Moderate |
| Margin trend | — | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: EMBC fair value analysis · ZTS fair value analysis